<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159091</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-RN-005</org_study_id>
    <nct_id>NCT03159091</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain additional data on efficacy and safety of Rengalin in&#xD;
      the treatment of cough in patients with stable obstructive pulmonary disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: multicenter, double-blind, randomized, parallel group placebo-controlled study.&#xD;
&#xD;
      The study will enroll men and women (aged 40 to 80 years) with cough associated with stable&#xD;
      chronic obstructive pulmonary disease (COPD). Subjects with COPD diagnosed more than 12&#xD;
      months earlier obtaining allowed basic therapy and retaining cough ≥2 points (according to&#xD;
      cough severity scale [CSS]) despite their therapy should be considered as the study&#xD;
      candidates.&#xD;
&#xD;
      After signing patient information leaflet (informed consent form) to participate in the&#xD;
      clinical study, collection of medical history and objective examination are performed, cough&#xD;
      severity is assessed (using CSS; at baseline evaluation of diurnal and nocturnal cough the&#xD;
      number of episodes and cough severity in the preceding day is taken into account) as well as&#xD;
      intensity of COPD effect on the subject (САТ test), concomitant therapy is recorded, computer&#xD;
      spirometry with evaluation of baseline FEV1/FVC and post-bronchodilator FEV1 (where&#xD;
      respiratory function cannot be assessed, the results of the previous examination dating no&#xD;
      more than 3 months earlier may be used). Females of childbearing potential will undergo&#xD;
      pregnancy test.&#xD;
&#xD;
      If a patient meets the inclusion criteria and does not demonstrate any of the exclusion&#xD;
      criteria at Visit 1 (Day 1), he/she is randomized to one of 2 groups: group 1 patients will&#xD;
      receive Rengalin at 2 tablets 3 times a day for 4 weeks; group 2 patients will receive&#xD;
      placebo using Rengalin dosing regimen for 4 weeks.&#xD;
&#xD;
      The patient will be monitored for 4 weeks (screening, randomization - before day 1, treatment&#xD;
      - 4 weeks). During follow-up period two visits are scheduled (Visit 1 (Day 1) and Visit 2&#xD;
      (Week 4) at which objective examination, recording cough severity (using CSS) will be carried&#xD;
      out, COPD effect on the subjects (САТ test) and concomitant therapy will be evaluated. At&#xD;
      Visit 2 (after 4-week treatment period) compliance will be additionally assessed.&#xD;
&#xD;
      At one of the clinical sites (Research Institute of Pulmonology, Russian FMBA), patients will&#xD;
      be monitored for cough on a daily basis (using the WHolter™ monitor), with the data used as&#xD;
      an additional measure to evaluate efficacy.&#xD;
&#xD;
      Subjects are allowed to take basic COPD therapy and medications for their co-morbidities in&#xD;
      the course of the study, except for the medicines listed in &quot;Prohibited concomitant&#xD;
      treatment&quot;.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2017</start_date>
  <completion_date type="Actual">April 25, 2019</completion_date>
  <primary_completion_date type="Actual">April 25, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With a Positive Treatment Response</measure>
    <time_frame>in 4 weeks of the treatment</time_frame>
    <description>Cough Severity Scale (CSS) total score. Cough intensity according to the scale is assessed in daytime and at night in points where 0 - no cough, 5 - continuous exhausting cough in daytime and at night. Response criterion: ≥1 lower total CSS score compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of Cough After 4 Weeks Compared to Baseline</measure>
    <time_frame>Baseline and 4 weeks after the treatment</time_frame>
    <description>Cough Severity Scale (CSS) total score. Cough intensity according to the scale is assessed in the daytime and at night in points, where 0 - no cough, 5 - continuous exhausting cough in the daytime, and at night.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With ≥50% Lesser Cough Severity at 4 Weeks</measure>
    <time_frame>in 4 weeks of the treatment</time_frame>
    <description>Number of Participants with a Decrease from Baseline of ≥50% in Cough Severity at 4 weeks. Based on the total Cough Severity Scale (CSS) score. Cough intensity according to the scale is assessed in the daytime and at night in points, where 0 - no cough, 5 - continuous exhausting cough in the daytime and at night.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Clinical Symptoms of Chronic Obstructive Pulmonary Disease (COPD)</measure>
    <time_frame>in 4 weeks of the treatment</time_frame>
    <description>Based on the total COPD Assessment Test (CAT) score. CAT consists of 8 items. Each item ranges from &quot;0&quot; to &quot;5&quot; balls. The total score ranges from minimum &quot;0&quot; to maximum &quot;40&quot; points. Higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With no Exacerbation of COPD</measure>
    <time_frame>in 4 weeks of the treatment</time_frame>
    <description>COPD exacerbation is defined as an acute event characterized by aggravation of the event within 2-3 or more days. Exacerbation manifests in intensification of respiratory disorders beyond their regular daily fluctuations and require administration of products in addition to the previously prescribed basic therapy as well as a rescue drug for symptom relief (salbutamol). Additional products include antibacterial drugs, systemic corticosteroids and/or emergency therapy (ambulance call) or hospitalization for COPD exacerbation.&#xD;
COPD exacerbation is recorded as an adverse event. If a COPD exacerbation develops within the first week of the subject participation in the study, it will not be considered as a secondary inefficacy criterion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">238</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Rengalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rengalin</intervention_name>
    <description>Oral administration.</description>
    <arm_group_label>Rengalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of both sexes aged from 40 to 80 years old.&#xD;
&#xD;
          2. COPD diagnosed (in accordance with the GOLD-2014 guidelines) ≥12 months before&#xD;
             inclusion.&#xD;
&#xD;
          3. Stable course of COPD (≥ 6 weeks free of disease progression).&#xD;
&#xD;
          4. Mild, moderate or severe degree of bronchial obstruction (FEV1/FVC &lt; 0.7;&#xD;
             post-bronchodilator FEV1 ≥30% of predicted value).&#xD;
&#xD;
          5. CSS score ≥2.&#xD;
&#xD;
          6. Stable dose of standard therapy within the preceding 4 weeks.&#xD;
&#xD;
          7. Use of and adherence to contraceptive methods by fertile-age patients of both sexes&#xD;
             during the study.&#xD;
&#xD;
          8. Availability of a signed patient information sheet (Informed Consent form) for&#xD;
             participation in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Earlier diagnosis of intra- or extrathoracic causes of cough (e.g., asthma, malignant&#xD;
             neoplasm of lung, tuberculosis, sarcoidosis, α1-antitrypsin deficiency,&#xD;
             bronchiectasis, cystic fibrosis, interstitial pulmonary diseases, perennial allergic&#xD;
             rhinitis, gastro-oesophageal reflux disease, use of ACE inhibitors, disease of upper&#xD;
             respiratory tract, etc.).&#xD;
&#xD;
          2. Cough associated with eating.&#xD;
&#xD;
          3. An exacerbation of COPD, acute upper and/or lower respiratory infection at inclusion&#xD;
             or in the previous 4 weeks.&#xD;
&#xD;
          4. Modifications to standard drug therapy (dose escalation, replacement of medicines&#xD;
             prescribed or addition of new medications) in the previous 4 weeks.&#xD;
&#xD;
          5. Very severe degree of bronchial obstruction (post-bronchodilator FEV1 &lt;30% pred or &lt;&#xD;
             50% and chronic respiratory failure).&#xD;
&#xD;
          6. Haemoptysis.&#xD;
&#xD;
          7. Stroke in the preceding 3 months or stroke with long-term residual neurological&#xD;
             deficit within 6 months before study entry.&#xD;
&#xD;
          8. Acute coronary syndrome, myocardial infarction within 6 months before study&#xD;
             enrollment.&#xD;
&#xD;
          9. Unstable or life-threatening arrhythmia in the previous 3 months.&#xD;
&#xD;
         10. Acute or chronic heart failure (NYHA (1964) Class III or IV).&#xD;
&#xD;
         11. Presence or suspicion of oncological disease.&#xD;
&#xD;
         12. Body Mass Index (BMI) ≤18 kg/m2 or ≥40 kg/m2.&#xD;
&#xD;
         13. Chronic kidney disease (categories С3-5 А3).&#xD;
&#xD;
         14. Hepatic failure (Child-Pugh class C)&#xD;
&#xD;
         15. Exacerbation or decompensation of a chronic disease that would affect the patient's&#xD;
             ability to participate in the clinical trial.&#xD;
&#xD;
         16. For smokers - intention to quit smoking in the next 4 weeks.&#xD;
&#xD;
         17. Allergy/intolerance to any of the components of medications used in the treatment.&#xD;
&#xD;
         18. Course intake of medicines listed in the section 'Prohibited concomitant treatment'&#xD;
             for 4 weeks prior to the enrollment in the trial.&#xD;
&#xD;
         19. Participation in other clinical trials within 3 months prior to the enrollment in this&#xD;
             study.&#xD;
&#xD;
         20. Patients who, from investigator's point of view, will fail to comply with the&#xD;
             observation requirements of the trial or with the dosing regimen of the&#xD;
             investigational drug.&#xD;
&#xD;
         21. Other conditions preventing the patient from normal participation (e.g., planned&#xD;
             business or other trips).&#xD;
&#xD;
         22. Drug addiction, alcohol use in the amount over 2 units of alcohol a day, mental&#xD;
             diseases.&#xD;
&#xD;
         23. Pregnancy, breast-feeding, unwillingness to use contraception during the study.&#xD;
&#xD;
         24. Patient is related to the research staff of the clinical investigative site who are&#xD;
             directly involved in the trial or is the immediate family member of the investigator.&#xD;
             The immediate family members include husband/wife, parents, children or brothers (or&#xD;
             sisters), regardless of whether they are natural or adopted.&#xD;
&#xD;
         25. Patient works for MATERIA MEDICA HOLDING company (i.e., is the company's employee,&#xD;
             temporary contract worker or appointed official responsible for carrying out the&#xD;
             research or their immediate family).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Regional state budgetary health care institution &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Barnaul</city>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional state budget health care institution &quot;City Hospital No. 5, Barnaul&quot;</name>
      <address>
        <city>Barnaul</city>
        <zip>656045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NUZ &quot;Road Clinical Hospital at the station Chelyabinsk JSC&quot; RZhD &quot;</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Budget Health Institution &quot;Regional Clinical Hospital No. 4&quot;</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Kazan Medical University&quot;/Central City Clinical Hospital and Clinic #18</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Kazan Medical University&quot;/Professor's Clinic</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pirogov Russian National Research Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Health Care of the Nizhny Novgorod Region &quot;City Clinical Hospital No. 10&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryazan State Medical University named after academician I.P. Pavlov</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North-Western State Medical University named after I.I. Mechnikov</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North-western State Medical University named after I.I.Mechnikov</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Public Health Institution &quot;Vvedensky City Clinical Hospital&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191180</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Federal State Institute of Public Health 'The Nikiforov Russian Center of Emergency and Radiation Medicine'</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Pavlov State Medical University of St. Petersburg</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Institution of Health &quot;City Polyclinic No. 106&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198328</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara City Hospital №4</name>
      <address>
        <city>Samara</city>
        <zip>443056</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Institution &quot;City Hospital No. 40 in the Kurortny District&quot;</name>
      <address>
        <city>Sestroretsk</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Voronezh Regional Clinical Hospital №1</name>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <results_first_submitted>October 12, 2020</results_first_submitted>
  <results_first_submitted_qc>November 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2020</results_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 17, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT03159091/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rengalin</title>
          <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).&#xD;
Rengalin: Oral administration.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).&#xD;
Placebo: Oral administration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Incorrect inclusion ineligible patient</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient has taken no dose of study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rengalin</title>
          <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).&#xD;
Rengalin: Oral administration.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).&#xD;
Placebo: Oral administration.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
            <count group_id="B2" value="117"/>
            <count group_id="B3" value="238"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="121"/>
                    <count group_id="B2" value="117"/>
                    <count group_id="B3" value="238"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="7.9"/>
                    <measurement group_id="B2" value="64.8" spread="8.4"/>
                    <measurement group_id="B3" value="64.3" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="121"/>
                    <count group_id="B2" value="117"/>
                    <count group_id="B3" value="238"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="121"/>
                    <count group_id="B2" value="117"/>
                    <count group_id="B3" value="238"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With a Positive Treatment Response</title>
        <description>Cough Severity Scale (CSS) total score. Cough intensity according to the scale is assessed in daytime and at night in points where 0 - no cough, 5 - continuous exhausting cough in daytime and at night. Response criterion: ≥1 lower total CSS score compared to baseline.</description>
        <time_frame>in 4 weeks of the treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rengalin</title>
            <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).&#xD;
Rengalin: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Positive Treatment Response</title>
          <description>Cough Severity Scale (CSS) total score. Cough intensity according to the scale is assessed in daytime and at night in points where 0 - no cough, 5 - continuous exhausting cough in daytime and at night. Response criterion: ≥1 lower total CSS score compared to baseline.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0422</p_value>
            <method>G-test (Chi-square)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Cough After 4 Weeks Compared to Baseline</title>
        <description>Cough Severity Scale (CSS) total score. Cough intensity according to the scale is assessed in the daytime and at night in points, where 0 - no cough, 5 - continuous exhausting cough in the daytime, and at night.</description>
        <time_frame>Baseline and 4 weeks after the treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rengalin</title>
            <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).&#xD;
Rengalin: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Cough After 4 Weeks Compared to Baseline</title>
          <description>Cough Severity Scale (CSS) total score. Cough intensity according to the scale is assessed in the daytime and at night in points, where 0 - no cough, 5 - continuous exhausting cough in the daytime, and at night.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" spread="1.42"/>
                    <measurement group_id="O2" value="4.12" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total score after 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="1.35"/>
                    <measurement group_id="O2" value="2.78" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>∆ between initial and 4 weeks total scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="1.38"/>
                    <measurement group_id="O2" value="1.35" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to ∆ between initial and 4 weeks total scores row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1101</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With ≥50% Lesser Cough Severity at 4 Weeks</title>
        <description>Number of Participants with a Decrease from Baseline of ≥50% in Cough Severity at 4 weeks. Based on the total Cough Severity Scale (CSS) score. Cough intensity according to the scale is assessed in the daytime and at night in points, where 0 - no cough, 5 - continuous exhausting cough in the daytime and at night.</description>
        <time_frame>in 4 weeks of the treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rengalin</title>
            <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).&#xD;
Rengalin: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With ≥50% Lesser Cough Severity at 4 Weeks</title>
          <description>Number of Participants with a Decrease from Baseline of ≥50% in Cough Severity at 4 weeks. Based on the total Cough Severity Scale (CSS) score. Cough intensity according to the scale is assessed in the daytime and at night in points, where 0 - no cough, 5 - continuous exhausting cough in the daytime and at night.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1373</p_value>
            <method>G-test (Chi-square)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Clinical Symptoms of Chronic Obstructive Pulmonary Disease (COPD)</title>
        <description>Based on the total COPD Assessment Test (CAT) score. CAT consists of 8 items. Each item ranges from &quot;0&quot; to &quot;5&quot; balls. The total score ranges from minimum &quot;0&quot; to maximum &quot;40&quot; points. Higher values represent a worse outcome.</description>
        <time_frame>in 4 weeks of the treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rengalin</title>
            <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).&#xD;
Rengalin: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Clinical Symptoms of Chronic Obstructive Pulmonary Disease (COPD)</title>
          <description>Based on the total COPD Assessment Test (CAT) score. CAT consists of 8 items. Each item ranges from &quot;0&quot; to &quot;5&quot; balls. The total score ranges from minimum &quot;0&quot; to maximum &quot;40&quot; points. Higher values represent a worse outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="6.8"/>
                    <measurement group_id="O2" value="20.3" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total score after 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" spread="6.9"/>
                    <measurement group_id="O2" value="17.8" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>∆ between initial and 4 weeks total scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="4.2"/>
                    <measurement group_id="O2" value="2.5" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0870</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With no Exacerbation of COPD</title>
        <description>COPD exacerbation is defined as an acute event characterized by aggravation of the event within 2-3 or more days. Exacerbation manifests in intensification of respiratory disorders beyond their regular daily fluctuations and require administration of products in addition to the previously prescribed basic therapy as well as a rescue drug for symptom relief (salbutamol). Additional products include antibacterial drugs, systemic corticosteroids and/or emergency therapy (ambulance call) or hospitalization for COPD exacerbation.&#xD;
COPD exacerbation is recorded as an adverse event. If a COPD exacerbation develops within the first week of the subject participation in the study, it will not be considered as a secondary inefficacy criterion</description>
        <time_frame>in 4 weeks of the treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rengalin</title>
            <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).&#xD;
Rengalin: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With no Exacerbation of COPD</title>
          <description>COPD exacerbation is defined as an acute event characterized by aggravation of the event within 2-3 or more days. Exacerbation manifests in intensification of respiratory disorders beyond their regular daily fluctuations and require administration of products in addition to the previously prescribed basic therapy as well as a rescue drug for symptom relief (salbutamol). Additional products include antibacterial drugs, systemic corticosteroids and/or emergency therapy (ambulance call) or hospitalization for COPD exacerbation.&#xD;
COPD exacerbation is recorded as an adverse event. If a COPD exacerbation develops within the first week of the subject participation in the study, it will not be considered as a secondary inefficacy criterion</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks (screening + randomization - up to 1 days, study therapy - 4 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rengalin</title>
          <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).&#xD;
Rengalin: Oral administration.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).&#xD;
Placebo: Oral administration.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza A (H1N1)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <description>Tinnitus on waking</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Angular cheilitis</sub_title>
                <description>Stuck in the corners of the mouth.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Labial herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Pain in the subscapularis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Sleep disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty passing sputum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itchy palms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>The rise in blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Worsening hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mikhail Putilovskiy, MD, PhD, Clinical and Medical Department Director</name_or_title>
      <organization>Materia Medica Holding</organization>
      <phone>+74952761571 ext 302</phone>
      <email>PutilovskiyMA@materiamedica.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

